After 30 years of development, therapy with monoclonal antibodies has started to realize its promise. Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 20 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Monoclonal antibodies may have a number of promising potential therapeutic applications in the treatment of cancer, autoimmune diseases, viral infections, asthma, and other diseases. Hepatitis B virus (HBV) is one of the main pathogens of hepatitis and hepatocarcinoma. Human plasma-derived Hepatitis B immune globulin (HBIG) is being used for prophylactic and liver transplantation currently. However, it is required to replace a HBIG with a recombinant one because of limited availability of human plasma with high anti-HBV antibody titer and possible contamination of human pathogens. In order to meet this requirements, we selected human antibody to the HBsAg from an anti-HBs Ab-enriched phage-display library and a Chinese hamster ovary (CHO) cell line, HBC7A, was established which produces a fully human IgG1 antibody against HBV. Mass production and purification processes were established and this mAb was characterized in terms of HBV neutralization and safety for the purpose of human trial for liver transplantation.
저자
Yong-Won Shin [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Kyung-Hwan Ryoo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Ki-Tae Bong [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Dong-Hyuck Seo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Kwang-Won Hong [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Ki-Hwan Chang [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Yong-Nam Shin [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Sun-Jeong Oh [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Bong-Sang Yoo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Jin-Seol Choi [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
Se-Ho Kim [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동